Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and ...

Novo Nordisk shares (DK:NOVO.B) (NVO) rose 5% in opening New York trade. The American depository receipts however have plunged 37% this year amid increased competition for its weight-loss drugs as ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

GoodRx (NASDAQ:GDRX) jumped 18% after revealing a partnership with Novo Nordisk (NYSE:NVO) to offer Ozempic and Wegovy to ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Investing.com -- GoodRx (NASDAQ: GDRX) stock surged 18% after announcing a collaboration with Novo Nordisk (NYSE: NVO) to offer Ozempic and Wegovy to eligible self-paying patients for $499 per month.

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Current health news highlights include UK investor backing in Assura's acquisition by PHP, Novo Nordisk's legal affairs over ...